Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spinning Around – One Company's Bid To Diagnostic-ify The Metabolism

Executive Summary

Lifespin is working on tools to characterize a patient’s metabolism and provide more detailed information about a disease.

You may also be interested in...



Minute Insight: Illumina Is Doing Stuff Again – More Leadership Changes

The sequencing technology company, led by an interim CEO, is further shuffling its leadership following the announcement of disappointing mid-year results.

Minute Insight: Maestro Cues The Music With CE Mark For Moon Surgical

The Paris-based start-up has picked up a CE mark for the latest generation of its Maestro system, a tool designed to make laparoscopic surgery easier and safer.

Minute Insight: 15,000 Surgeries And More Funding For CMR Surgical

The UK-based company has just raised $165m support the ongoing commercialization of the Versius robotic platform.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel